Loading...
Docoh

Cellectis (CLLS)

News

From Benzinga Pro
Goldman Sachs Maintains Sell on Cellectis, Lowers Price Target to $2
24 May 22
News, Price Target, Analyst Ratings
Goldman Sachs maintains Cellectis (NASDAQ:CLLS) with a Sell and lowers the price target from $3 to $2.
71 Biggest Movers From Yesterday
20 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
38 Stocks Moving In Thursday's Mid-Day Session
19 May 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
18 May 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Baird Upgrades Cellectis to Outperform
18 May 22
News, Upgrades, Analyst Ratings
Baird analyst Jack Allen upgrades Cellectis (NASDAQ:CLLS) from Neutral to Outperform.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
17 May 22
Pre-Market Outlook, Markets, Movers
Barclays Maintains Overweight on Cellectis, Lowers Price Target to $7
13 May 22
News, Price Target, Analyst Ratings
Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and lowers the price target from $9 to $7.
Cellectis Q1 EPS $(0.64) Down From $(0.26) YoY, Sales $3.83M Down From $27.97M YoY
12 May 22
Earnings, News
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share. This is a 146.15 percent decrease over losses of $(0.26) per share from the same period last year. The company reported $3.83 million in sales this
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut
27 Apr 22
Biotech, News, Penny Stocks, Health Care, Financing, Offerings, IPOs, General
Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma
11 Apr 22
Biotech, News, Penny Stocks, Health Care, General
Cellectis To Present Preclinical Data On UCART20x22 At AACR Apr. 10
8 Apr 22
Biotech, News, Events, General
Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR T has been designed and engineered on the TRAC / CD52
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
16 Mar 22
Biotech, News, Penny Stocks, Health Care, Small Cap, General
Iovance Biotherapeutics Reports Its Investigational New Drug Application Allowed To Proceed For TALEN-Edited Tumor Infiltrating Lymphocyte
15 Mar 22
Biotech, News, FDA, General
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages
Cathie Wood's Ark Sits Out Thursday's Dip In Favorite Stocks
11 Mar 22
Cryptocurrency, News, Penny Stocks, Sector ETFs, Broad U.S. Equity ETFs, Short Ideas, Small Cap, Markets, Tech, Trading Ideas, ETFs
Popular stock picker Cathie Wood's Ark Investment Management on Thursday stayed away from buying more shares in favorite stocks on the dip. The St. Petersburg, Florida-based Ark Invest’s daily data revealed a total of seven trades and none of them were among the top constituents in any of its actively-traded exchange funds.
Stocks That Hit 52-Week Lows On Monday
7 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 524 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
4 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 368 stocks hit new 52-week lows.
Recap: Cellectis Q4 Earnings
3 Mar 22
Earnings
Cellectis (NASDAQ:CLLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cellectis beat estimated earnings by 47.83%, reporting an EPS of $-0.48 versus an estimate of $-0.92.
UPDATE: Cellectis Q4 Adj. EPS $(0.48) Beats $(0.92) Estimate
3 Mar 22
Earnings, News
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.92) by 47.83 percent. This is a 45.45 percent increase over losses of $(0.88) per share from the
Cellectis Q4 EPS $(0.55) Beats $(0.92) Estimate, Sales $13.66M Beat $8.72M Estimate
3 Mar 22
Earnings, News
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.92) by 40.22 percent. This is a 37.5 percent increase over losses of $(0.88) per share from the same

Press releases

From Benzinga Pro
Cellectis' Annual Shareholders' General Meeting to be Held on June 28, 2022
23 May 22
Press Releases
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
16 May 22
Press Releases
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
12 May 22
Earnings, Press Releases
◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity ◦ Published two articles in Nature Communications providing preclinical validation for the
Cellectis to Report First Quarter 2022 Financial Results
5 May 22
News, Press Releases
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
5 May 22
Earnings, Press Releases
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
27 Apr 22
News, Financing, Press Releases
Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cellsCytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting
8 Apr 22
News, Health Care, Press Releases
Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR T has been designed and engineered on the TRAC / CD52 TALEN® platform UCART20x22 expected to be
Iovance Biotherapeutics' Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
15 Mar 22
Health Care, Press Releases
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages
Cellectis to Participate in Two Upcoming Investor Conferences in March
11 Mar 22
News, Press Releases
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
Thinking about buying stock in Excellon Resources, Cellectis, Superior Drilling Products, Safe T Group, or Drive Shack?
11 Mar 22
Opinion, Press Releases
NEW YORK, March 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXN, CLLS, SDPI, SFET, and DS.
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results
3 Mar 22
Earnings, Press Releases
Encouraging preliminary results from BALLI-01 study (evaluating UCART22) in relapsed/refractory B-cell Acute Lymphoblastic Leukemia presented at ASH 2021 annual meeting; BALLI-01 currently enrolling at DL3 On track